GUTS vs. ATRC, MDXG, AORT, CATX, SILK, ATRI, KIDS, EMBC, FNA, and PLSE
Should you be buying Fractyl Health stock or one of its competitors? The main competitors of Fractyl Health include AtriCure (ATRC), MiMedx Group (MDXG), Artivion (AORT), Perspective Therapeutics (CATX), Silk Road Medical (SILK), Atrion (ATRI), OrthoPediatrics (KIDS), Embecta (EMBC), Paragon 28 (FNA), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Fractyl Health (NASDAQ:GUTS) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.
AtriCure received 544 more outperform votes than Fractyl Health when rated by MarketBeat users. However, 100.00% of users gave Fractyl Health an outperform vote while only 68.98% of users gave AtriCure an outperform vote.
AtriCure has higher revenue and earnings than Fractyl Health.
Fractyl Health currently has a consensus target price of $22.00, suggesting a potential upside of 226.41%. AtriCure has a consensus target price of $49.78, suggesting a potential upside of 120.84%. Given Fractyl Health's higher possible upside, research analysts clearly believe Fractyl Health is more favorable than AtriCure.
In the previous week, AtriCure had 4 more articles in the media than Fractyl Health. MarketBeat recorded 10 mentions for AtriCure and 6 mentions for Fractyl Health. AtriCure's average media sentiment score of 1.09 beat Fractyl Health's score of 0.46 indicating that AtriCure is being referred to more favorably in the news media.
99.1% of AtriCure shares are held by institutional investors. 3.2% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Fractyl Health has a net margin of 0.00% compared to AtriCure's net margin of -8.98%. Fractyl Health's return on equity of 0.00% beat AtriCure's return on equity.
Summary
AtriCure beats Fractyl Health on 8 of the 14 factors compared between the two stocks.
Get Fractyl Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GUTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fractyl Health Competitors List
Related Companies and Tools
